3-month disability progression reduced with fingolimod


REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – An analysis of data from the phase III FREEDOMS trial of fingolimod in relapsing-remitting MS reports that 3-month disability progression is reduced by about one-third overall, with reductions seen consistently across all predefined subgroups (Devonshire et al. AAN 2011; abstract P01.198).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page